Pharming Group Announces Third Quarter 2026 Revenues Above Market Expectations

Pharming Group N.V. reported third quarter 2026 revenues that exceeded market expectations, driven by its ongoing commercialization of protein replacement therapies and precision medicines for rare diseases, such as RUCONEST and Joenja. The announcement underscores the company's operational progress in the biopharmaceutical sector.